Table 1.
Baseline characteristics
| Low dose group (n=36) | Middle dose group (n=36) | High dose group (n=36) | ||
|---|---|---|---|---|
| Age, years | ||||
| 18–29 | 9 (25%) | 12 (33%) | 10 (28%) | |
| 30–39 | 13 (36%) | 14 (39%) | 15 (42%) | |
| 40–49 | 8 (22%) | 3 (8%) | 7 (19%) | |
| 50–60 | 6 (17%) | 7 (19%) | 4 (11%) | |
| Mean age, years | 37·2 (10·7) | 36·3 (11·5) | 35·5 (10·1) | |
| Sex | ||||
| Male | 18 (50%) | 19 (53%) | 18 (50%) | |
| Female | 18 (50%) | 17 (47%) | 18 (50%) | |
| Mean body-mass index, kg/m2 | 23·3 (2·7) | 23·9 (2·7) | 24·1 (3·1) | |
| Underlying diseases* | ||||
| Yes | 1 (3%) | 2 (6%) | 4 (11%) | |
| No | 35 (97%) | 34 (94%) | 32 (89%) | |
| Pre-existing adenovirus type-5 neutralising antibody | ||||
| Mean GMT | 168·9 (13·9) | 149·5 (10·5) | 115·0 (13·4) | |
| ≤200, titre | 16 (44%) | 17 (47%) | 20 (56%) | |
| >200, titre | 20 (56%) | 19 (53%) | 16 (44%) | |
Data are n (%) or mean (SD). GMT=geometric mean titre.
*
Seven participants had hypertension, chronic bronchitis, gout, or were a carrier of hepatitis B virus.